Inspired by the EU mission regarding fighting cancer, this project commits to contribute to tackle this major societal challenge. The "Europe's Beating Cancer Plan", presented in 2021, has four striking targets: prevention, reduce the time to diagnosis, optimize diagnosis and treatment using personalized medicine and support the quality of life of all people exposed to cancer. This project contributes to diagnosis and follow up of the disease using prostate cancer (PCa) as a case study. More and more biomarkers are discovered and validated for cancer and the highly precise determination thereof is high on the priority list, necessitating analytical devices that allow rapid and accurate analysis with high sensitivity. Therefore, I propose the combined use of electrochemical detection with a light-triggered sensing technology for the specific and selective photoelectrochemical detection of low concentrations of three different classes of PCa biomarkers (i.e. non-coding RNA, gene fusion transcript and DNA single nucleotide polymorphism). Through the development of a 96-well plate detection platform, I will be able to perform a panel analysis of those biomarkers in 96 samples simultaneously. Detection and quantification of the selected target sequences will be performed in three different liquid biopsies (i.e. urine, plasma and serum), to ensure the translation from a lab technology to a device for hospitals.